Pfizer's Weight-Loss Ambition: A Strategic Pivot Amid Transition

Pfizer navigates post-COVID revenue decline and patent cliffs with a monthly obesity drug candidate and a high dividend yield to retain investors during its strategic pivot.

Pharmaceutical giant Pfizer is navigating a complex transitional period. As revenues from its COVID-related products diminish and key patent cliffs approach, the company is making a substantial strategic bet on the lucrative obesity drug market. Investors are being offered a substantial dividend yield exceeding 6% as an incentive to stay patient while the company's new pipeline of treatments is developed.

Financial Headwinds and Valuation Pressure

The company's current financial landscape presents significant challenges. Pfizer's revenue forecast for the full year 2026 stands between $59.5 and $62.5 billion, a figure below its 2025 performance. This decline is primarily driven by the ongoing reduction in COVID-19 product sales (Comirnaty and Paxlovid), which are projected to fall to approximately $5 billion—a fraction of their pandemic-era peaks.

Compounding these pressures is the impending loss of exclusivity for several blockbuster drugs. Major revenue drivers, including the blood thinner Eliquis and the cancer treatment Ibrance, are set to face generic competition in the period leading up to 2030. Market analysts view the stock's current valuation, trading at a price-to-earnings ratio of just under 9, as a reflection of these substantial risks. This multiple sits notably below both the company's historical average and broader industry benchmarks. The shares recently traded at €23.30, having recovered somewhat from their 52-week low of €19.28.

A Monthly Contender in the Obesity Arena

At the heart of Pfizer's future strategy is its obesity drug pipeline. In early February 2026, the company announced positive data from a Phase 2b clinical trial (VESPER-3) for a novel drug candidate. A potential key differentiator from established treatments by Novo Nordisk and Eli Lilly is its dosing frequency: Pfizer's candidate aims for a monthly injection schedule, contrasting with the weekly regimens of current market leaders.

The study demonstrated a weight-reducing effect of up to 12.3%, positioning the drug as a potentially competitive product. To accelerate its path to market, Pfizer has planned an extensive clinical program involving more than 20 studies this year alone, with the goal of securing regulatory approval by 2028. Success would provide a compelling option for patients seeking a less frequent dosing schedule.

The Dividend as a Bridge to Future Growth

For shareholders willing to wait, the company's dividend policy offers a measure of compensation. Pfizer recently distributed its 349th consecutive quarterly dividend. The current dividend yield of 6.2% acts as a buffer for investors while the company executes its strategic transformation. Beyond obesity, Pfizer has also recorded recent successes in oncology, notably securing full FDA approval for a combination therapy targeting colorectal cancer, which should support growth in that segment.

The year 2026 will prove critical in determining whether Pfizer's innovation engine can offset the declining revenues from its legacy products. A key near-term event for investors is scheduled for June 6, when detailed results from the VESPER-3 study will be presented at the American Diabetes Association meeting. This data release will be pivotal in assessing Pfizer's ability to credibly challenge the current leaders in the obesity treatment market.